| abstract |
The present invention provides spiro-oxazolones acting as V1a receptor modulators, in particular as V1a receptor antagonists, their preparation, pharmaceutical compositions containing them and their use as medicaments. This compound acts peripherally and centrally in vasopressin secretion abnormalities, anxiety, depressive disorder, obsessive compulsive disorder, autism spectrum disorder, schizophrenia, aggressive behavior and phase shift sleep disorder, especially jet lag It is useful as a treatment. |